Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SPERO HEALTH OF TENNESSEE, LLC

NPI: 1538628904 · SMYRNA, TN 37167 · Substance Use Disorder Rehabilitation Clinic/Center · NPI assigned 03/15/2019

$23.45M
Total Medicaid Paid
123,208
Total Claims
93,434
Beneficiaries
13
Codes Billed
2019-11
First Month
2024-12
Last Month

Provider Details

Authorized OfficialADAMS, RICK (CFO)
NPI Enumeration Date03/15/2019

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2019 17 $3K
2020 2,317 $539K
2021 21,276 $4.57M
2022 31,720 $6.70M
2023 31,056 $6.48M
2024 36,822 $5.15M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
H0016 Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) 42,055 34,801 $9.44M
H0014 Alcohol and/or drug services; ambulatory detoxification 24,412 13,946 $6.42M
H0033 Oral medication administration, direct observation 34,910 26,451 $5.91M
H0047 Alcohol and/or other drug abuse services, not otherwise specified 2,085 1,939 $970K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 5,013 4,274 $304K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 4,470 3,813 $228K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3,714 3,054 $115K
90853 Group psychotherapy (other than of a multiple-family group) 2,294 1,902 $22K
G2087 Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month 1,254 1,026 $19K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 1,438 960 $12K
90832 Psychotherapy, 30 minutes with patient 659 589 $8K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 861 636 $6K
96160 43 43 $0.23